[8-K] MicroStrategy Incorporated 8.00% Series A Perpetual Strike Preferred Stock Reports Material Event
Item 5.02 8-K: On 18 Jul 2025 Lixte Biotechnology appointed Jason Sawyer and Dr. Michael Holloway as independent directors under designation rights granted to investors that bought 3,573,190 Series B Preferred Shares on 3 Jul 2025. Sawyer also becomes Chair of the Compensation Committee and joins the Audit Committee.
To accommodate the appointments, Dr. Stephen Forman and Dr. Yun Yen resigned from the Board and moved to the company’s Scientific Advisory Committee. The company states these departures were not due to disagreements.
Separately, Chief Medical Officer Dr. Jan Schellens tendered his resignation and his consulting agreement will end 31 Jul 2025 so he can pursue other opportunities; no disputes were cited.
No financial results, guidance, or operational metrics were provided—this filing is strictly a corporate-governance update linked to the recent preferred-equity financing.
Voce 5.02 8-K: Il 18 luglio 2025 Lixte Biotechnology ha nominato Jason Sawyer e il Dr. Michael Holloway come amministratori indipendenti, in base ai diritti di designazione concessi agli investitori che hanno acquistato 3.573.190 azioni privilegiate di Serie B il 3 luglio 2025. Sawyer è inoltre diventato Presidente del Comitato per la Remunerazione e membro del Comitato di Revisione.
Per permettere queste nomine, il Dr. Stephen Forman e il Dr. Yun Yen si sono dimessi dal Consiglio di Amministrazione e sono passati al Comitato Consultivo Scientifico dell’azienda. La società dichiara che tali dimissioni non sono state causate da disaccordi.
Separatamente, il Direttore Medico, Dr. Jan Schellens, ha rassegnato le dimissioni e il suo contratto di consulenza terminerà il 31 luglio 2025 per permettergli di perseguire altre opportunità; non sono state segnalate controversie.
Non sono stati forniti risultati finanziari, previsioni o indicatori operativi: questa comunicazione riguarda esclusivamente un aggiornamento sulla governance aziendale legato al recente finanziamento tramite azioni privilegiate.
Artículo 5.02 8-K: El 18 de julio de 2025, Lixte Biotechnology nombró a Jason Sawyer y al Dr. Michael Holloway como directores independientes bajo los derechos de designación otorgados a los inversores que adquirieron 3.573.190 acciones preferentes Serie B el 3 de julio de 2025. Sawyer también se convierte en presidente del Comité de Compensación y se une al Comité de Auditoría.
Para facilitar estos nombramientos, el Dr. Stephen Forman y el Dr. Yun Yen renunciaron al Consejo y pasaron al Comité Asesor Científico de la empresa. La compañía afirma que estas salidas no se debieron a desacuerdos.
Por separado, el Director Médico, Dr. Jan Schellens, presentó su renuncia y su contrato de consultoría finalizará el 31 de julio de 2025 para poder buscar otras oportunidades; no se mencionaron disputas.
No se proporcionaron resultados financieros, previsiones ni métricas operativas; esta presentación es estrictamente una actualización de la gobernanza corporativa vinculada a la reciente financiación mediante acciones preferentes.
항목 5.02 8-K: 2025년 7월 18일, Lixte Biotechnology는 2025년 7월 3일에 3,573,190주의 시리즈 B 우선주를 매입한 투자자에게 부여된 지명 권한에 따라 Jason Sawyer와 Dr. Michael Holloway를 독립 이사로 임명했습니다. Sawyer는 또한 보상 위원회 의장직을 맡고 감사 위원회에도 합류합니다.
이 임명을 수용하기 위해 Dr. Stephen Forman과 Dr. Yun Yen은 이사회에서 사임하고 회사의 과학 자문 위원회로 이동했습니다. 회사는 이들의 사임이 이견 때문이 아니라고 밝혔습니다.
별도로, 최고 의료 책임자 Dr. Jan Schellens는 사임 의사를 밝혔으며, 그의 컨설팅 계약은 2025년 7월 31일 종료되어 다른 기회를 추구할 예정입니다; 분쟁은 없었습니다.
재무 실적, 가이드라인 또는 운영 지표는 제공되지 않았으며, 이번 보고는 최근 우선주 자금 조달과 관련된 기업 거버넌스 업데이트에 한정됩니다.
Point 5.02 8-K : Le 18 juillet 2025, Lixte Biotechnology a nommé Jason Sawyer et le Dr Michael Holloway en tant qu’administrateurs indépendants, conformément aux droits de désignation accordés aux investisseurs ayant acquis 3 573 190 actions privilégiées de série B le 3 juillet 2025. Sawyer devient également président du comité de rémunération et rejoint le comité d’audit.
Pour faciliter ces nominations, le Dr Stephen Forman et le Dr Yun Yen ont démissionné du conseil d’administration et ont rejoint le comité consultatif scientifique de la société. La société précise que ces départs ne résultent pas de désaccords.
Séparément, le directeur médical, Dr Jan Schellens, a présenté sa démission et son contrat de consultant prendra fin le 31 juillet 2025 afin qu’il puisse poursuivre d’autres opportunités ; aucun différend n’a été signalé.
Aucun résultat financier, prévision ou indicateur opérationnel n’a été communiqué – ce dépôt constitue strictement une mise à jour de la gouvernance d’entreprise liée au récent financement par actions privilégiées.
Position 5.02 8-K: Am 18. Juli 2025 ernannte Lixte Biotechnology Jason Sawyer und Dr. Michael Holloway als unabhängige Direktoren, basierend auf den Designationsrechten, die Investoren eingeräumt wurden, die am 3. Juli 2025 3.573.190 Series B Vorzugsaktien erworben hatten. Sawyer wird zudem Vorsitzender des Vergütungsausschusses und Mitglied des Prüfungsausschusses.
Um die Ernennungen zu ermöglichen, traten Dr. Stephen Forman und Dr. Yun Yen aus dem Vorstand zurück und wechselten in den Wissenschaftlichen Beirat des Unternehmens. Das Unternehmen erklärt, dass diese Abgänge nicht auf Meinungsverschiedenheiten zurückzuführen sind.
Separat reichte der Chief Medical Officer Dr. Jan Schellens seinen Rücktritt ein, und sein Beratungsvertrag endet am 31. Juli 2025, damit er andere Möglichkeiten verfolgen kann; es wurden keine Streitigkeiten genannt.
Es wurden keine Finanzergebnisse, Prognosen oder operative Kennzahlen bereitgestellt – diese Einreichung ist ausschließlich ein Update zur Unternehmensführung im Zusammenhang mit der jüngsten Vorzugsaktienfinanzierung.
- Preferred-shareholder representation adds two independent directors, potentially strengthening oversight and aligning new capital with governance.
- Reassignment of departing directors to the Scientific Advisory Committee retains domain expertise, limiting knowledge loss.
- Chief Medical Officer resignation may slow clinical development and poses leadership continuity risk.
- Multiple board departures in a short window can create strategic uncertainty and distract management.
Insights
TL;DR: Board expands to include preferred-shareholder nominees; independent oversight rises, but key executive exits.
The Series B investors have swiftly exercised their right to place two nominees on the Board, increasing shareholder representation and potentially improving governance. Sawyer’s instant elevation to Compensation Committee chair implies influence over pay policy. Reassignment of Forman and Yen to the Scientific Advisory Committee preserves institutional knowledge, mitigating disruption. However, simultaneous turnover of three directors plus the CMO creates near-term execution risk. Overall impact appears balanced.
TL;DR: Governance shuffle after financing; CMO departure raises pipeline execution questions.
Adding investor-backed directors may speed strategic decisions and signal confidence from new capital. Yet losing the CMO during clinical development could delay trials, require recruiting costs, and unsettle partner discussions. Because no programs were referenced, the operational effect is uncertain but potentially negative if replacement lags. Net impact: neutral-to-slightly negative until a suitable scientific leader is hired.
Voce 5.02 8-K: Il 18 luglio 2025 Lixte Biotechnology ha nominato Jason Sawyer e il Dr. Michael Holloway come amministratori indipendenti, in base ai diritti di designazione concessi agli investitori che hanno acquistato 3.573.190 azioni privilegiate di Serie B il 3 luglio 2025. Sawyer è inoltre diventato Presidente del Comitato per la Remunerazione e membro del Comitato di Revisione.
Per permettere queste nomine, il Dr. Stephen Forman e il Dr. Yun Yen si sono dimessi dal Consiglio di Amministrazione e sono passati al Comitato Consultivo Scientifico dell’azienda. La società dichiara che tali dimissioni non sono state causate da disaccordi.
Separatamente, il Direttore Medico, Dr. Jan Schellens, ha rassegnato le dimissioni e il suo contratto di consulenza terminerà il 31 luglio 2025 per permettergli di perseguire altre opportunità; non sono state segnalate controversie.
Non sono stati forniti risultati finanziari, previsioni o indicatori operativi: questa comunicazione riguarda esclusivamente un aggiornamento sulla governance aziendale legato al recente finanziamento tramite azioni privilegiate.
Artículo 5.02 8-K: El 18 de julio de 2025, Lixte Biotechnology nombró a Jason Sawyer y al Dr. Michael Holloway como directores independientes bajo los derechos de designación otorgados a los inversores que adquirieron 3.573.190 acciones preferentes Serie B el 3 de julio de 2025. Sawyer también se convierte en presidente del Comité de Compensación y se une al Comité de Auditoría.
Para facilitar estos nombramientos, el Dr. Stephen Forman y el Dr. Yun Yen renunciaron al Consejo y pasaron al Comité Asesor Científico de la empresa. La compañía afirma que estas salidas no se debieron a desacuerdos.
Por separado, el Director Médico, Dr. Jan Schellens, presentó su renuncia y su contrato de consultoría finalizará el 31 de julio de 2025 para poder buscar otras oportunidades; no se mencionaron disputas.
No se proporcionaron resultados financieros, previsiones ni métricas operativas; esta presentación es estrictamente una actualización de la gobernanza corporativa vinculada a la reciente financiación mediante acciones preferentes.
항목 5.02 8-K: 2025년 7월 18일, Lixte Biotechnology는 2025년 7월 3일에 3,573,190주의 시리즈 B 우선주를 매입한 투자자에게 부여된 지명 권한에 따라 Jason Sawyer와 Dr. Michael Holloway를 독립 이사로 임명했습니다. Sawyer는 또한 보상 위원회 의장직을 맡고 감사 위원회에도 합류합니다.
이 임명을 수용하기 위해 Dr. Stephen Forman과 Dr. Yun Yen은 이사회에서 사임하고 회사의 과학 자문 위원회로 이동했습니다. 회사는 이들의 사임이 이견 때문이 아니라고 밝혔습니다.
별도로, 최고 의료 책임자 Dr. Jan Schellens는 사임 의사를 밝혔으며, 그의 컨설팅 계약은 2025년 7월 31일 종료되어 다른 기회를 추구할 예정입니다; 분쟁은 없었습니다.
재무 실적, 가이드라인 또는 운영 지표는 제공되지 않았으며, 이번 보고는 최근 우선주 자금 조달과 관련된 기업 거버넌스 업데이트에 한정됩니다.
Point 5.02 8-K : Le 18 juillet 2025, Lixte Biotechnology a nommé Jason Sawyer et le Dr Michael Holloway en tant qu’administrateurs indépendants, conformément aux droits de désignation accordés aux investisseurs ayant acquis 3 573 190 actions privilégiées de série B le 3 juillet 2025. Sawyer devient également président du comité de rémunération et rejoint le comité d’audit.
Pour faciliter ces nominations, le Dr Stephen Forman et le Dr Yun Yen ont démissionné du conseil d’administration et ont rejoint le comité consultatif scientifique de la société. La société précise que ces départs ne résultent pas de désaccords.
Séparément, le directeur médical, Dr Jan Schellens, a présenté sa démission et son contrat de consultant prendra fin le 31 juillet 2025 afin qu’il puisse poursuivre d’autres opportunités ; aucun différend n’a été signalé.
Aucun résultat financier, prévision ou indicateur opérationnel n’a été communiqué – ce dépôt constitue strictement une mise à jour de la gouvernance d’entreprise liée au récent financement par actions privilégiées.
Position 5.02 8-K: Am 18. Juli 2025 ernannte Lixte Biotechnology Jason Sawyer und Dr. Michael Holloway als unabhängige Direktoren, basierend auf den Designationsrechten, die Investoren eingeräumt wurden, die am 3. Juli 2025 3.573.190 Series B Vorzugsaktien erworben hatten. Sawyer wird zudem Vorsitzender des Vergütungsausschusses und Mitglied des Prüfungsausschusses.
Um die Ernennungen zu ermöglichen, traten Dr. Stephen Forman und Dr. Yun Yen aus dem Vorstand zurück und wechselten in den Wissenschaftlichen Beirat des Unternehmens. Das Unternehmen erklärt, dass diese Abgänge nicht auf Meinungsverschiedenheiten zurückzuführen sind.
Separat reichte der Chief Medical Officer Dr. Jan Schellens seinen Rücktritt ein, und sein Beratungsvertrag endet am 31. Juli 2025, damit er andere Möglichkeiten verfolgen kann; es wurden keine Streitigkeiten genannt.
Es wurden keine Finanzergebnisse, Prognosen oder operative Kennzahlen bereitgestellt – diese Einreichung ist ausschließlich ein Update zur Unternehmensführung im Zusammenhang mit der jüngsten Vorzugsaktienfinanzierung.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| |
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class |
Trading |
Name of Each Exchange on which Registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events. |
On July 21, 2025, MicroStrategy® Incorporated d/b/a Strategy™ (the “Company”) issued a press release announcing that, subject to market and other conditions, it intends to conduct an initial public offering of 5,000,000 shares of its Variable Rate Series A Perpetual Stretch Preferred Stock. A copy of the press release is filed hereto as Exhibit 99.1 and is incorporated herein by reference.
Neither this Current Report on Form 8-K nor the press release filed hereto constitutes an offer to sell or the solicitation of an offer to buy any securities.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit No. |
Description | |
| 99.1 | Press Release of MicroStrategy Incorporated, dated July 21, 2025. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 21, 2025 | MicroStrategy Incorporated (Registrant) | |||||
| By: | /s/ W. Ming Shao | |||||
| Name: | W. Ming Shao | |||||
| Title: | Executive Vice President & General Counsel | |||||
FAQ
Why did LIXT file an 8-K on 21 Jul 2025?
Who are the new directors of Lixte Biotechnology (LIXT)?
Did any directors resign from LIXT?
What committees will Jason Sawyer join?
When does CMO Dr. Jan Schellens leave LIXT?
Were the resignations due to disagreements with the company?
